- Home
- NRC vs CELC Comparison
NRC vs CELC Comparison
Compare NRC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- CELC
- Stock Information
- Founded
- NRC 1981
- CELC 2011
- Country
- NRC United States
- CELC United States
- Employees
- NRC N/A
- CELC N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- CELC Medical Specialities
- Sector
- NRC Health Care
- CELC Health Care
- Exchange
- NRC Nasdaq
- CELC Nasdaq
- Market Cap
- NRC 394.2M
- CELC 327.3M
- IPO Year
- NRC N/A
- CELC 2017
- Fundamental
- Price
- NRC $14.04
- CELC $10.61
- Analyst Decision
- NRC
- CELC Strong Buy
- Analyst Count
- NRC 0
- CELC 6
- Target Price
- NRC N/A
- CELC $30.17
- AVG Volume (30 Days)
- NRC 101.8K
- CELC 193.7K
- Earning Date
- NRC 04-28-2025
- CELC 05-14-2025
- Dividend Yield
- NRC 3.44%
- CELC N/A
- EPS Growth
- NRC N/A
- CELC N/A
- EPS
- NRC 1.02
- CELC N/A
- Revenue
- NRC $141,298,000.00
- CELC N/A
- Revenue This Year
- NRC N/A
- CELC N/A
- Revenue Next Year
- NRC N/A
- CELC N/A
- P/E Ratio
- NRC $13.71
- CELC N/A
- Revenue Growth
- NRC N/A
- CELC N/A
- 52 Week Low
- NRC $9.76
- CELC $7.58
- 52 Week High
- NRC $35.81
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- NRC 63.42
- CELC 51.67
- Support Level
- NRC $13.28
- CELC $9.51
- Resistance Level
- NRC $14.11
- CELC $11.43
- Average True Range (ATR)
- NRC 0.71
- CELC 0.76
- MACD
- NRC 0.28
- CELC -0.02
- Stochastic Oscillator
- NRC 95.38
- CELC 51.16
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.